Tubulis is proud to announce the appointment of Björn Hock, PhD, as its new Chief Development Officer (CDO). With more than two decades of experience in the field of antibody-based therapeutics, including antibody-drug-conjugates (ADCs), Dr. Hock is a powerful addition to the company’s leadership team. In his role as CDO, Dr. Hock will focus on driving rapid preclinical development strategies for Tubulis’ current drug candidates in oncology. He will also be responsible for designing and executing biomarker studies and investigating novel antibody-drug-combinations to further broaden the company’s pipeline of uniquely matched ADCs for a range of indications.
Björn has been a valuable asset to Tubulis since 2020, providing invaluable guidance and creative input as we develop our ADC platform technologies and product candidates. As Chief Development Officer, his commitment to our mission of ushering in a new ADC era and delivering better outcomes for patients has been a critical driving force behind the advancement and expansion of our pipeline. We are truly grateful for his extended support.
Dr. Hock is excited to join Tubulis and support the team in furthering their ADC candidates towards clinical evaluation and exploring novel ADC concepts to bring new treatment opportunities to patients. With its differentiated and proprietary technologies that cover all aspects of ADC development, Tubulis has become an up-and-coming leader in the field of ADC design. Dr. Hock is eager to help them bring these promising treatments to those who need them most.
The Supervisory Board of Tubulis is thrilled to welcome Björn as Chief Development Officer, having seen the attraction of the opportunity that Tubulis represents. Chairman Christian Grøndahl, PhD, has praised the leadership for its commitment in assembling a top-notch team.
Dr. Hock has had an impressive career in the field of biochemistry, having successfully developed multiple platform technologies and therapeutic programs from concept to lead candidate stage. His most recent achievement was his role as interim CEO at Aerium Therapeutics (formerly SwissThera SA), wherein he built up the European office and accelerated the preclinical development of anti-SARS-CoV-2 antibody assets to human trials in only 8 months. Before that, he held various positions at Merck KGaA for over a decade, with his last post being Senior Director and Global Head of ADC and Targeted Therapeutics, where he led the development of various protein therapeutics from concept to lead stage. With a PhD in Biochemistry from the Chemotherapeutisches Forschungsinstitut Georg Speyer-Haus in Frankfurt, Dr. Hock has made remarkable strides in the industry.
At Tubulis, we are revolutionizing the therapeutic potential of antibody-drug conjugates (ADCs) by combining novel proprietary technologies with disease-specific biologic insight. Our approach allows us to generate uniquely matched protein-drug conjugates, overcoming constraints of toxicity, efficacy and indication. We are building an ever-expanding pipeline of new conjugates and partnering with industry leaders to bring about a new era of ADCs and better patient outcomes.